3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
4
Triple Negative Breast Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Hematopoietic and Lymphatic System Neoplasm
1
Graft vs Host Disease
1
Cholangiocarcinoma
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Cyclophosphamide
34
Doxorubicin
24
fludarabine phosphate
20
Vinblastine
20
Nivolumab
20
Dacarbazine
20
Brentuximab Vedotin
20
pembrolizumab
19
fludarabine
18
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
15
Filgrastim
13
Melphalan
12
Granulocyte Colony-Stimulating Factor
10
Gemcitabine
10
Bleomycin
10
Tacrolimus
9
Radiotherapy
9
Prednisone
9
Peripheral Blood Stem Cell Transplantation
9
Busulfan
9
Specimen Handling
8
Vincristine
7
Sirolimus
7
Magnetic Resonance Spectroscopy
7
Cyclosporine
7
pegfilgrastim
6
Stem Cell Transplantation
6
Bendamustine Hydrochloride
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
axatilimab
×
1 year
×
Clear all
NCT05723055
2026-05-08
NAHL
University of Utah
Phase 2
Active not recruiting
9 enrolled